BRIEF-Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results

Rapport Therapeutics

Rapport Therapeutics

RAPP

0.00

April 21 (Reuters) - Rapport Therapeutics Inc RAPP.O:

  • RAPPORT THERAPEUTICS PRESENTS RAP-219 FOCAL ONSET SEIZURE PHASE 2A FOLLOW-UP PERIOD RESULTS DEMONSTRATING SUSTAINED SEIZURE REDUCTION AT THE 2026 AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

  • RAPPORT THERAPEUTICS INC: RAP-219 WAS GENERALLY WELL TOLERATED THROUGHOUT TREATMENT AND FOLLOW-UP PERIODS

Source text: ID:nGNXc7bNXC

Further company coverage: RAPP.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.